Amwell® Announces Results for Second Quarter 2025BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the second quarter ended June 30. The company’s second quarter earnings report may be viewed at investors.amwell.com.
Amwell® to report second quarter 2025 operating results; company leaders to attend upcoming investor conferencesBOSTON, July 22, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report second quarter 2025 operating results after stock market trading hours on Tuesday, Aug. 5.
Amwell makes grant to new employee under inducement planBOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to one new employee. The grant was offered as material inducement to the employee’s employment with Amwell. The RSUs will vest as follows, subject to the employee’s continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date (“Initial Vesting Date”), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first calendar day of the month following the date that is three months following the Initial Vesting Date) for three years until such RSUs are vested in full.
Amwell® Announces Results for First Quarter 2025BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March 31. Visit Amwell’s investor relations website at investors.amwell.com to view the first quarter 2025 earnings report.
Amwell® to participate in upcoming investor conferencesBOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will participate in the following upcoming investor conferences:
Amwell® to report first quarter 2025 operating resultsBOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leader in digital care, will report first quarter 2025 operating results after stock market trading hours on Thursday, May 1 2025.
The Future of Healthcare: 10 Predictions For The Next DecadeThe healthcare industry stands on the brink of a transformative decade, driven by rapid advancements in technology, shifting demographics, and evolving patient expectations. Over the next ten years, we will witness groundbreaking changes that redefine how care is delivered, diseases are treated, and wellness is maintained. Below, we explore ten
Amwell makes inducement grantBOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leader in technology-enabled care, today announced that, on March 3, 2025, it made a grant of restricted stock units (“RSUs”) covering 220,844 shares of its Class A common stock to Dan Zamansky. The grant was offered as material inducement to Zamansky’s employment as Amwell’s chief product and technology officer. The RSUs become vested as follows, subject to Zamansky’s continued employment through each vesting date, except as noted below: 25% of the RSUs will vest on the six-month anniversary of the grant date (“Initial Vesting Date”), and the remaining 75% of the RSUs will vest in equal pro-rata increments every three (3) months thereafter (beginning on the first calendar day of the month following the date that is three months following the Initial Vesting Date) until such RSUs are fully vested on the first day of the calendar month following the four (4) year anniversary of the grant date. If Zamansky’s employment is terminated by the company without cause or by Zamansky with good reason, conditioned on Zamansky’s execution and non-revocation of a release of claims, the aforementioned grant will vest as to the portion that would have vested had Zamansky remained employed by the company through the first anniversary of his termination date. In addition, if the involuntary termination of employment occurs one month before or within 24 months following a change in control, the aforementioned grant will fully vest at the time of termination.
Amwell® makes grants to new employees under inducement planBOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leading technology-enabled care platform provider, announced that on Feb. 18, Amwell made grants of RSUs covering an aggregate of 16,737 shares of its Class A common stock to four new employees. The grants were offered as material inducement to the employees’ employment with Amwell. The RSUs will vest as follows, subject to the applicable employee’s continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date (“Initial Vesting Date”), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first calendar day of the month following the date that is three months following the Initial Vesting Date) for three years until such RSUs are vested in full.
Amwell® to participate in upcoming investor conferenceBOSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, will participate in an upcoming investor conference. Ido Schoenberg, M.D., Amwell chairman and chief executive officer, will participate in a fireside chat and one-on-one meetings at the TD Cowen 24th Annual Health Care conference in Boston on March 4. The fireside chat will be at 9:10 a.m. ET and an audio webcast of the fireside chat will be available at investors.amwell.com.
Amwell® Announces Results for Fourth Quarter and Full Year 2024BOSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. Visit Amwell’s investor relations website at investors.amwell.com to view the fourth quarter and full year 2024 earnings report.
Amwell® to report fourth quarter and full year 2024 operating resultsBOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Amwell® (
NYSE: AMWL), a leader in digital care, will report fourth quarter 2024 operating results after stock market trading hours on Wednesday, Feb. 12.
